TCTR20200520001
Not yet recruiting
未知
Investigating the Efficacy and Safety of Oroxylum Indicum Extract on Overweight and Obese Subjects: A Randomized Controlled Clinical Trial (A Pilot Study)
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Overweight,
- Sponsor
- Suranaree University of Technology
- Enrollment
- 100
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The inclusion criteria: men and women 30 to 60 years of age, affected by overweight or obesity, with the body mass index (BMI) of 25â€35 kg/m2 and without a previous diagnosis of cardiovascular disease
Exclusion Criteria
- •(1\) coronary heart diseases, e.g. heart failure, myocardial infarction, arrhythmia; (2\) endocrine disease, e.g. sex gland disorder, thyroid disorder, and pituitary disorder; (3\) pregnant or lactating women; (4\) taking medications or supplements and herbals that might interfere with blood glucose and lipid measurements. Subjects were excluded if they had side effects from the extract.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Evaluation the safety and effectiveness of Oxiplex Gel for reduction of pain and associated symptoms followingsingle level lumbar discectomyIRCT20141209020258N106Arak University of Medical Sciences60
Completed
Phase 2
EVALUATION OF EFFICACY AND SAFETY OF TOPICAL OXYMETAZOLINE 0.1% OPHTHALMIC SOLUTION IN TREATMENT OF ACQUIRED PTOSISHealth Condition 1: H024- Ptosis of eyelidCTRI/2022/08/044783DR RPCENTRE FOR OPHTHALMIC SCIENCES20
Recruiting
Phase 2
Determination of efficacy and safety of Oxaliplatin in locally advanced breast cancer patientsIRCT20181224042104N1Shiraz University of Medical Sciences30
Active, not recruiting
Not Applicable
Efficacy and safety of solithromycin in patients with gonorrhea.gonorrhoeaTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2014-004040-36-Outside-EU/EEACempra Pharmaceuticals, Inc.300
Recruiting
Phase 3
Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19IRCT20080901001165N51Sina Darou Laboratories Company80